For decades, Medicare was barred from covering weight-loss drugs outright. Seniors could only get GLP-1 medications like Wegovy or Zepbound through Part D if they had a qualifying medical diagnosis — type 2 diabetes, obstructive sleep apnea, or cardiovascular disease — not simply for obesity. That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, a short-term demonstration built to test affordable weight-management drug access ahead of a possible permanent policy.
This guide walks through exactly which drugs are covered, who qualifies, how to enroll, and — just as important — what the Bridge does not do, so you can decide whether it's worth pursuing with your doctor. If you are also exploring manufacturer support, see our Lilly Cares guide and our Mounjaro patient assistance overview.
What Is the Medicare GLP-1 Bridge Program?
The Bridge is a CMS demonstration project authorized under Medicare's Part D demonstration authority. It runs July 1, 2026 through December 31, 2027 — an 18-month window that CMS extended from its original six-month plan. It's explicitly designed as a stopgap: CMS is using the Bridge to gather real-world utilization data while evaluating a possible longer-term policy called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health). The BALANCE Model's Part D component was postponed indefinitely in April 2026, making the Bridge the only Medicare pathway for obesity GLP-1s through at least 2027.
Unlike a normal drug benefit, the Bridge sits outside your regular Part D plan. Claims are processed through a single, centralized CMS payment system rather than your individual Part D insurer — which is also why the copay doesn't interact with your plan's deductible or out-of-pocket limit.
Which Drugs Are Covered — and Which Aren't
This is the detail most seniors get wrong. The Bridge covers exactly three products, and only in specific formulations.
| Drug | Active ingredient | Formulation covered | Status |
|---|---|---|---|
| Wegovy® | Semaglutide | Injection and tablet | Covered |
| Zepbound® | Tirzepatide | KwikPen® only | Covered |
| Zepbound® (single-dose pen or vial) | Tirzepatide | Single-dose pen / vial | Not covered |
| Foundayo® | Orforglipron | Tablet | Covered |
| Ozempic® | Semaglutide | Injection | Not covered under Bridge* |
| Mounjaro® | Tirzepatide | Injection | Not covered under Bridge* |
| Rybelsus® | Semaglutide | Tablet | Not covered under Bridge* |
Foundayo (Orforglipron) Under the Medicare GLP-1 Bridge
Foundayo (orforglipron) is the first once-daily oral GLP-1 pill approved by the FDA for chronic weight management — no injections, no refrigeration, and no food or water restrictions. It was approved on April 1, 2026, and CMS added it to the Bridge on April 6, 2026.
| Feature | Foundayo | Wegovy | Zepbound KwikPen |
|---|---|---|---|
| Form | Once-daily tablet | Injection or tablet | Multi-dose injection pen |
| Refrigeration | No | Injection: yes; Tablet: no | Yes |
| Food/water restrictions | None | Injection: none; Tablet: per label | None |
| Bridge copay | $50/month | $50/month | $50/month |
Who Foundayo is best for: Patients who want GLP-1 weight-loss results without injections, travel frequently, or have needle anxiety. Average weight loss in trials was 12.4% at the highest dose over 72 weeks.
*Important nuance: Ozempic, Mounjaro, and Rybelsus are diabetes-indicated drugs. They can still be covered under your standard Part D benefit if prescribed for type 2 diabetes — they're just not part of the Bridge's weight-management pathway. If you're already receiving one of these through Part D for a medical diagnosis, keep using that coverage rather than switching to the Bridge.
Medicare GLP-1 Bridge Eligibility: BMI Criteria & Requirements
You must meet all four of these structural requirements:
- You have Medicare Part D drug coverage — either a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan that includes drug coverage (MA-PD).
- Your plan type is eligible. Private fee-for-service (PFFS) plans, cost contract plans, and PACE organizations are excluded.
- You are not currently receiving a GLP-1 through your Part D plan for type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH) — if you are, stay on that coverage instead.
- You meet the clinical BMI criteria below, either now or at the point you first started GLP-1 therapy.
| Tier | BMI Requirement | Required Condition |
|---|---|---|
| Tier 1 | 35 or higher | None — automatic qualification |
| Tier 2 | 30 or higher | Heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a or above) |
| Tier 3 | 27 or higher | Prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease |
Starting BMI counts: If you began GLP-1 therapy before July 1, 2026, your doctor can attest to the BMI you had when you started — not your current weight. Someone who started at BMI 37 and dropped to 34 can still qualify.
What the Bridge Program Does Not Cover
The $50 price tag is attractive, but the Bridge has real limitations that don't always make the headlines.
- It doesn't count toward your Part D deductible or your $2,100 annual out-of-pocket cap — the copay sits entirely outside that accounting.
- Medicare Extra Help cannot be applied — the $50 stays fixed regardless of income, and no manufacturer coupons can reduce it further.
- It's not eligible for the Medicare Prescription Payment Plan (the "smoothing" program that lets you spread other Part D costs across the year).
- It's temporary. Coverage is scheduled to end December 31, 2027. The related BALANCE Model has already launched in Medicaid, but as of mid-2026 its Part D component — which would have expanded coverage to Ozempic, Mounjaro, and Rybelsus for weight loss — has been postponed indefinitely. If you need a formulary exception for a non-Bridge drug, that route is still separate.
How Much Does the Bridge Cost?
| Drug | Typical cash price (highest dose) | Bridge copay |
|---|---|---|
| Zepbound® KwikPen | Up to $699/month | $50/month |
| Wegovy® injection | $149–$699/month | $50/month |
| Wegovy® tablet | Up to $299/month | $50/month |
| Foundayo® tablet | Up to $349/month | $50/month |
Cash prices vary by dose, pharmacy, and manufacturer savings programs, and typically rise as you move to higher maintenance doses over time. The Bridge's $50 copay stays flat no matter how your dose changes, which is the core financial advantage of enrolling.
How to Enroll: Step-by-Step
Confirm your Part D plan type
Check that you're in a standalone PDP or an MA-PD plan. If you're unsure what type of coverage you have, call 1-800-MEDICARE (1-800-633-4227).
Talk to your doctor
Discuss whether a Bridge-covered GLP-1 is medically appropriate, and confirm your BMI and any qualifying conditions meet the criteria above.
Your doctor submits prior authorization
Unlike a typical prescription, the prior authorization request goes to a centralized CMS processor — not your Part D plan. This is a new workflow for many prescribers, so ask your doctor's office whether they've submitted a Bridge prior authorization before, and build in time for possible delays.
Verify your identity at the pharmacy
Once approved, your pharmacy may contact you to confirm your Medicare ID number, printed on your Medicare card, so the claim can be processed through the Bridge's billing system.
Pay the flat $50 copay
You pay $50 for a 30-day supply, regardless of which covered drug or dose you're prescribed.
Plan for delays. Because the Bridge prior authorization process is new and routed through a central processor rather than individual plans, some prescribers and pharmacies experienced early processing delays around the July 1, 2026 launch. If your prescription doesn't go through immediately, ask your doctor's office to confirm the prior authorization was actually submitted to the CMS processor rather than your Part D plan.
How Long Does Medicare GLP-1 Bridge Approval Take?
Because the Bridge uses a centralized CMS processor rather than your individual Part D plan, timelines differ from standard prior authorizations:
- Standard processing: 5–10 business days from the time your doctor submits the prior authorization to the CMS central processor.
- Pharmacy verification: After approval, your pharmacy may need 1–2 business days to confirm your Medicare ID and process the first claim.
- Refills: Once approved, you do not need new prior authorization for refills or dose changes on the same drug.
Expect early delays. Because the Bridge launched July 1, 2026 and uses a new central billing system, some pharmacies and prescribers experienced processing backlogs in the first weeks. If your prescription doesn't go through, ask your doctor's office to confirm the prior auth was submitted to the CMS Bridge processor — not your regular Part D plan.
Can I Switch from Ozempic or Mounjaro to the Medicare GLP-1 Bridge?
It depends on your diagnosis — not your preference.
| Your Situation | Can You Use the Bridge? | What to Do Instead |
|---|---|---|
| Taking Ozempic/Mounjaro for type 2 diabetes | No | Keep using standard Part D — diabetes is a covered indication |
| Taking Zepbound for moderate-to-severe OSA | No | Keep using standard Part D — OSA is a covered indication |
| Taking any GLP-1 for fatty liver disease (MASH) | No | Keep using standard Part D — MASH is a covered indication |
| Taking Ozempic off-label for weight loss with no diabetes/OSA/MASH | Yes | Ask your doctor to switch your prescription to Wegovy, Zepbound, or Foundayo and submit a Bridge prior auth |
| Not currently on any GLP-1; seeking weight-loss treatment | Yes (if BMI eligible) | See your doctor to discuss Bridge-covered options |
Important: If you falsely claim you don't have diabetes/OSA/MASH to get Bridge coverage, your doctor's attestation is subject to CMS audit. The Bridge is for beneficiaries who genuinely do not have a Part D-covered indication for GLP-1s.
Key Dates to Remember
- July 1, 2026: Medicare GLP-1 Bridge officially begins.
- Ongoing: Enrollment in the Bridge itself isn't tied to the annual Medicare Open Enrollment window — it runs through your existing Part D plan once your prior authorization is approved.
- Oct 15 – Dec 7, 2026: Annual Enrollment Period (AEP) — a good time to confirm your Part D plan is still an eligible plan type for the Bridge going into 2027.
- December 31, 2027: Current scheduled end date for the Bridge demonstration.